26 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson’s Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada
14 August, 2020 in Featured Home, GB Sciences, Media, Press Release, Science GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson’s Disease and Neuropathic Pain
31 October, 2019 in GB Sciences, Media, Press Release, Science GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
19 March, 2019 in GB Sciences, Media, Press Release, Science GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.
13 March, 2019 in GB Sciences, Media, Press Release, Science GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue
08 March, 2019 in GB Sciences, Media, Press Release, Science Statement From LSU AgCenter on False Allegations Made by LDAF Commissioner
